Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sierra Oncology Inc (SRRA)

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,757
  • Shares Outstanding, K 10,396
  • Annual Sales, $ 0 K
  • Annual Income, $ -88,280 K
  • 60-Month Beta 1.42
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -1.68
  • Number of Estimates 3
  • High Estimate -1.43
  • Low Estimate -1.90
  • Prior Year -6.80
  • Growth Rate Est. (year over year) +75.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.02 +7.29%
on 09/24/20
12.76 -15.75%
on 08/28/20
-1.75 (-14.00%)
since 08/25/20
3-Month
10.02 +7.29%
on 09/24/20
14.32 -24.93%
on 08/20/20
-2.09 (-16.28%)
since 06/25/20
52-Week
8.55 +25.80%
on 03/18/20
22.00 -51.14%
on 12/09/19
-5.65 (-34.45%)
since 09/25/19

Most Recent Stories

More News
Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib

Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib

AIMT : 34.33 (+0.09%)
DVAX : 4.48 (+3.70%)
NVS : 87.11 (+0.94%)
SRRA : 10.75 (+1.90%)
Sierra Oncology Reports Second Quarter 2020 Results

Sierra Oncology Reports Second Quarter 2020 Results

GILD : 62.25 (unch)
SRRA : 10.75 (+1.90%)
Sierra Oncology, Inc (SRRA) Upgraded to Buy: What Does It Mean for the Stock?

Sierra Oncology, Inc (SRRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SRRA : 10.75 (+1.90%)
Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders

Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announces the election of new independent directors, Alison Moore, Ph.D. and Stephen Dilly,...

CDXS : 11.81 (+1.11%)
SRRA : 10.75 (+1.90%)
Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib

- Data presented at the 25(th) European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and favorable hematological safety profile of momelotinib -- Long-term...

SRRA : 10.75 (+1.90%)
Sierra Oncology Announces Presentations at Upcoming Investor Conferences

- Oppenheimer Biotech by the Lake 2020 Investor Summit at 11:25 a.m. ET on May 28(th) -- Jefferies Global Virtual Healthcare Conference at 4:30 p.m. ET on June 3(rd) -

SRRA : 10.75 (+1.90%)
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer

- Mr. Craig Collard appointed to the Board of Directors -

SRRA : 10.75 (+1.90%)
Sierra Oncology to Report Favorable Dose Intensity Data and Long-Term Safety Data for Momelotinib at the 25th European Hematology Association (EHA) Congress

- Momelotinib's demonstrable anemia benefit and low myelosuppressive potential facilitate sustained dose intensity and prolonged clinical activity -

SRRA : 10.75 (+1.90%)
Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis

- Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 10:00 am ET on Wednesday, May 13(th) -

SRRA : 10.75 (+1.90%)
Sierra Oncology Reports First Quarter 2020 Results

- Company continues to operationalize the MOMENTUM Phase 3 clinical trial in myelofibrosis - - Impact of COVID-19 uncertain but may potentially affect overall MOMENTUM timelines -- Publications highlighting...

SRRA : 10.75 (+1.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SRRA with:

Business Summary

Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central...

See More

Key Turning Points

2nd Resistance Point 11.71
1st Resistance Point 11.23
Last Price 10.75
1st Support Level 10.44
2nd Support Level 10.13

See More

52-Week High 22.00
Fibonacci 61.8% 16.86
Fibonacci 50% 15.27
Fibonacci 38.2% 13.68
Last Price 10.75
52-Week Low 8.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar